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IMMUNOGENETIC ANALYSIS IN CLL: BIOLOGICAL AND
CLINICAL RELEVANCE
Pivotal studies from the 1990s offered the ﬁrst pieces of evidence
for the role of immunoglobulin (IG) receptors and antigen
stimulation in the natural history of chronic lymphocytic leukemia
(CLL). These studies revealed the pronounced skewing of the IG
gene repertoire in CLL, strongly implying a role for antigen
selection in disease development.1–4 In addition, they showed that
the presence and load of somatic hypermutation (SHM) within the
rearranged IG heavy variable (IGHV) genes of the clonotypic B-cell
receptor (BcR) IG dichotomizes CLL into two broad categories: the
ﬁrst includes cases with no or limited SHM (‘unmutated’ CLL,
U-CLL), while the second includes cases with a signiﬁcant SHM
load (‘mutated’ CLL, M-CLL).1,3 Of note, within the clinical arena,
IGHV mutation burden enabled the accurate prediction of the
clinical course of the disease based on the level of SHM within the
expressed IGHV genes.5,6 It has subsequently been shown that
U-CLL is markedly different from M-CLL not only regarding the
clinical course, but also in terms of biological features: the former
is associated with adverse prognostic genomic aberrations,
increased BcR signaling capacity, shorter time to progression
and an overall inferior outcome compared to M-CLL.7
In hindsight, these studies represent true landmarks in the
understanding of CLL, forming the cornerstone for an immuno-
logically oriented view of CLL ontogeny and evolution. Indeed,
rather than focusing only on genomic lesions, as is the norm for
most cancers including almost all other lymphoid malignancies,
these studies highlighted the critical role of the BcR IG, thus
opening new directions for research into CLL-microenvironment
interactions that have led to a more comprehensive appreciation
of the biological heterogeneity of CLL.8–10
An important milestone in the timeline of CLL-focused
immunogenetic research was the observation that one-third of
CLL patients carry (quasi)identical, also refered to as stereotyped
BcR IGs, and can be classiﬁed into subsets deﬁned by distinctive
sequence motifs within the IG variable heavy complementarity-
determining region 3 (VH CDR3).11–13 Mounting evidence suggests
that patients assigned to the same subset have similar biological
features (for example, signaling capacity14,15 and genomic
aberration proﬁles16–19) and clinical course, often differing
signiﬁcantly from other patients within the same SHM
category.20–22 On these grounds, it has been proposed that
patient classiﬁcation based on BcR IG stereotypy can supersede
the more generic categorization into U-CLL versus M-CLL, at least
for major subsets. For instance, stereotyped subset #2 (IGHV3-21/
IGLV3-21) has emerged as a prototype of aggressive disease
independently of the SHM load.23
Additional evidence for the importance of immunogenetic
analysis in CLL was provided by three recent independent studies
demonstrating that the SHM status of the IGHV genes was
associated with a particular clinical response to chemoimmu-
notherapy regimens in both clinical trials and general practice,
such as the FCR (ﬂudarabine/cyclophosphamide/rituximab) com-
bination. More speciﬁcally, ﬁt M-CLL patients treated with FCR
(especially those lacking del(17p) and/or del(11q)) experienced
more prolonged responses, delayed progression and a signiﬁcant
improvement in overall survival compared to U-CLL patients who
received the same treatment.24–26 Determining the SHM level is
therefore important, not only for general assessment of the
disease course in CLL, but also for guiding treatment decisions:
put simply, it is not only a prognostic test, but also a predictive
test for the use of certain therapies, such as FCR. This will likely
have important implications in the near future due to the
emergence of novel treatments and will impact the clinical
management of patients with CLL.
SETTING STANDARDS FOR IMMUNOGENETIC ANALYSIS IN
CLL: PAST AND ONGOING ERIC INITIATIVES
ERIC, the European Research Initiative on CLL (www.ericll.org) has
been at the forefront of immunogenetic research in CLL. The ﬁrst
ERIC recommendations for the determination of IGHV gene
mutational status in CLL were published in 2007.27 They were
subsequently complemented by instructions detailing how to
handle analytically challenging cases or cases difﬁcult to
categorize.28 In addition, since 2007, ERIC provides the community
with an expert online forum (www.ericll.org/services/) to discuss
general queries on IG gene sequence interpretation in CLL, or to
analyze and provide advice about actual IG gene rearrangement
sequences that can be difﬁcult to interpret in everyday practice.
More recently, ERIC participated in the development of the
ARResT/AssignSubsets bioinformatics tool, which is freely available
online, and enables one to robustly and easily determine whether
a particular IGHV-IGHD-IGHJ gene rearrangement belongs to one
of the so-called ‘major’ (that is, largest) CLL stereotyped subsets.29
To improve the quality of IG gene sequence analysis in CLL
within the international research community, ERIC has organized
educational workshops on the topic (2009–2016: Uppsala, Paris,
Thessaloniki, Stresa, Brno, Uppsala). Furthermore, it has estab-
lished the IG Network with the main objective of harmonizing IG
gene sequence analysis in CLL to ensure that results are reliable
and comparable among different laboratories, hence promoting
optimal patient care (www.ericll.org/pages/networks/ignetwork).
In this context, very recently, ERIC also started periodic (biannual)
rounds of certiﬁcation of IG gene sequence analysis in CLL to
disseminate expertise in reliable IG sequence analysis (www.ericll.
org/pages/ighv-certiﬁcation). Thirty-seven diagnostic laboratories
from 17 different countries in Europe and Australia have already
participated in the ﬁrst certiﬁcation round and passed this test.
UPDATE OF THE ERIC RECOMMENDATIONS FOR
IMMUNOGENETIC ANALYSIS IN CLL
Capitalizing on many years of active involvement in this ﬁeld
combined with the experience gained from the activities
mentioned above, we recently critically discussed all aspects of
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Table 1. Technical considerations for determination of the IGHV somatic hypermutation status of clonotypic IGHV-IGHD-IGHJ gene rearrangements
in CLL
Item Recommendations Remarks
Material
Anticoagulants EDTA (or CPT)
Cells/tissue Blood, bone marrow, tissue biopsy Puriﬁcation of B cells usually not necessary unless low
fraction of leukemic cells
Nucleic acid gDNA or cDNA cDNA useful when mutations within the IGHJ gene impair
ampliﬁcation
Production of template for sequencing
Primers 5′: leader VH FR1, VH FR2 and VH FR3 primers are not acceptable
3′: IGHJ or IGHC IGHC primers (on cDNA) useful when mutations within IGHJ
gene impair ampliﬁcation
Ampliﬁcation Multiplex PCR individual PCR reactions (for each 5′ primer) may be useful
when more than one rearrangement found
Detection of IGH
rearrangement
GeneScan or PAGE electrophoresis Agarose gel electrophoresis strongly discouraged (lack of
resolution)
Cloning Not necessary Except in rare circumstances (more than one rearrangement
not isolated by simplex PCR)
Sequencing
Methodology Direct, both strands Both strands mandatory for high-quality sequence
Sequence alignment IMGT/V-QUEST (www.imgt.org) Adjustable parameters: (1) search for insertions/deletions; (2)
number of accepted D genes
IGHV identity (%) Automatic or adjusted Adjusted: use option ‘search for insertions/deletions’ when
low % identity
Stereotypic subset
identiﬁcation
ARResT/AssignSubsets (bat.infspire.org/arrest/
ericll.org/pages/services/tool)
Applicable for the current 19 major BcR stereotyped subsets
in CLLa
Abbreviations: BcR, B-cell receptor; cDNA, complementary DNA; CLL, chronic lymphocytic leukemia; CPT, citrate/pyridoxal 5′-phosphate/Tris; EDTA,
ethylenediaminetetraacetic acid; gDNA, genomic DNA; PAGE, polyacrylamide gel electrophoresis. aAgathangelidis and colleagues.7
Table 2. Reporting IGHV gene somatic hypermutation status in CLL
Item Recommendations
Standard cases
Methodology Report type of: primers,a PCR product analysis, sequencing method, bioinformatics
tools
Gene identiﬁcation IGHV, IGHD, IGHJ genes and alleles; IGHD may be difﬁcult to precisely identify (due to
deletions and/or SHM)
Productive rearrangement Mutational status determined only for productive rearrangements; if unproductive,
mention reasons (out-of-frame junction, stop codon)
IGHV gene: % of nucleotide identity to germ line Classiﬁcation: U-CLL ⩾ 98%; M-CLL o98%; borderline CLL when 97–97.9%
Subset identiﬁcation For subsets with well-established prognostic value (subsets #1, #2, #4 and #8)
Difﬁcult cases (frequencyb)
Double rearrangements (10.5%)
Productive+non-productive concordant status
(7.8%)
Same as standard cases (mutational status deﬁned by the productive rearrangement)
Productive+non-productive discordant status
Productive U+non-productive M (0.4%) Mutational status not determined
Productive M+non-productive U (0.2%) Consider as M-CLL
Double productive
Concordant status (1.3%) Same as standard cases
Discordant status (0.7%) Mutational status not determined
Multiple (more than two) productive
rearrangementsc
Mutational status not determined (unless it can be performed on sorted B-cell clones
and predominant clones are easily identiﬁed)
Single unproductive rearrangement (0.6%) Mutational status not determined (after failure of alternative PCR attempts)
Missing anchors (C104/W118) (0.4%) Mutational status possible if evidence for IG expression on leukemic cells and/or
preserved G-X-G motif in VH FR4
Abbreviations: CLL, chronic lymphocytic leukemia; IG, immunoglobulin; M-CLL, mutated CLL; U-CLL, unmutated CLL. aLeader primers are the only
recommended option. That said, in rare cases when leader primers are unsuccessful at providing a product that can be sequenced and VH FR1 primers
are used (discouraged for the determination of SHM status), the report should indicate that the use of VH FR1 primers might underestimate the total
number of IGHV somatic hypermutations as a part of the VH domain is missing. bAll frequencies according to Langerak et al.28 cCases with two or more B-cell
clones.32
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immunogenetics for diagnostic purposes in CLL, bearing in mind
new knowledge available, and reached a consensus on the
essential requirements necessary for reliable and reproducible IG
gene analysis and interpretation of CLL-speciﬁc IGHV-IGHD-IGHJ
gene rearrangements. The updated ERIC recommendations are
listed in Tables 1 and 2. In the sections that follow, we will focus
on the most critical revisions and additions to the original
recommendations from 2007.27
Primers
Only the use of leader primers allows for the ampliﬁcation
of the entire sequence of the rearranged IGHV gene, thus
enabling the true and complete level of SHM to be determined,
and is the recommended choice. The use of primers annealing
to the VH FR1 or even more downstream parts of the VH
domain (for example, the VH FR2 or VH FR3) is not acceptable
for determining the SHM status: in these cases, an insufﬁcient
portion of the IG gene rearrangement will be ampliﬁed,
thus potentially obscuring or preventing the true level of SHM
from being determined since the total number of IGHV SHMs
may be underestimated. That said, in rare cases when leader
primers are unsuccessful at providing a product that can be
sequenced and VH FR1 primers are used (not generally
recommended), the report should indicate that the use of
VH FR1 primers might underestimate the total number of
IGHV SHMs.
Sequence alignment and annotation
1. Alignment tool and database. The user sequence is analyzed
using IMGT/V-QUEST, the analysis tool for rearranged nucleo-
tide sequences of IMGT, the international ImMunoGeneTics
information system (www.imgt.org). IMGT/V-QUEST (up to 50
per batch online) provides the identiﬁcation of the closest germ
line V and J genes and alleles, and comprises the results of the
integrated IMGT/JunctionAnalysis for the detailed analysis of
the junction and the identiﬁcation of the D genes and alleles
for IGH gene rearrangements.
2. Nomenclature. The IMGT/V-QUEST reference directory against
which the user sequences are analyzed includes the sequences
of the germ line IMGT V, D and J genes and alleles, approved by
the Human Gene Nomenclature Committee, endorsed by NCBI
and at the origin of Immunoinformatics (journal.frontiersin.org/
article/10.3389/ﬁmmu.2014.00022/full).
IMGT/V-QUEST terms and standards for CLL sequence analysis
interpretation are detailed in Supplementary Material.
Reporting the results of immunogenetic analysis in CLL
As for every diagnostic test, rigorous standards and meticulous
attention to details are of utmost importance. Therefore, every
laboratory report should:
1. List the identiﬁed IGHV, IGHD and IGHJ genes and alleles.
Occasionally, reliable IGHD gene assignment is difﬁcult or
impossible, especially in rearrangements with short VH CDR3
sequences and/or due to multiple SHM; this should be clearly
stated in the report (‘IGHD gene and allele assignment: not
possible’), but without raising any concern or ﬂagging as an
important detail.
2. State whether the particular IGHV-IGHD-IGHJ gene rearrange-
ment is productive or unproductive. Essential criteria for
considering a rearrangement as productive include the
utilization of a functional IGHV gene and an in-frame VDJ
junction bearing the anchors of the VH CDR3, namely
cysteine C104 (2nd-CYS) and tryptophan W118 (J-TRP) (the
latter part of the W-G-X-G motif of the J-REGION in VH FR4).
For unproductive rearrangements, the underlying reason
(for example, out-of-frame junction or stop codon) should
be mentioned. Before reporting an unproductive rearrange-
ment as a deﬁnitive result in clinical routine, one should
take particular attention to carefully review the ﬂow cytometry
result for the presence of surface immunoglobulin, as well as
the sequence at the nucleotide level and the chromatogram,
and make additional attempts on either the same or different
starting material using the same or different primer sets to
exclude technical ﬂaws during the initial ampliﬁcation,
sequencing or immunoinformatic analytical steps.
3. Specify the percentage of identity of the identiﬁed rearranged
IGHV gene and allele to its closest germ line counterpart.
4. State whether the identiﬁed productive IG gene rearrangement
leads to membership of a major stereotyped subset. Consider-
ing ever-increasing evidence about the clinical implications of
BcR IG stereotypy, at least for certain major stereotyped
subsets,10–12 the IG Network advises everyone to analyze the
clonal IGHV-IGHD-IGHJ gene rearrangement for possible
membership in aggressive (major) subsets. Particular attention
should be given to the identiﬁcation of subset #2 (IGHV3-21/
IGL3-21) as most cases belonging to this subset would be
otherwise reported as M-CLL, given the presence of a moderate
level of SHM, usually leading to an identity to the germ line
below the 98% cutoff. It is now well established that patients
belonging to subset #2 have an inferior outcome, similar to
U-CLL patients and patients with TP53 aberrations.12 Member-
ship in other major stereotyped subsets can also be explicitly
reported, namely the aggressive #1 (IGHV clan I genes/IGKV1
(D)-39) and #8 (IGHV4-39/IGKV1(D)-39), the latter also asso-
ciated with the highest risk for Richter’s transformation among
all CLL, as well as subset #4 (IGHV4-34) that includes a
subgroup of patients with a particularly indolent form of CLL
and rarely in need of treatment, which might be relevant for
both patients and physicians alike.10 Membership to any of
these subsets can be investigated using the ARResT/Assign-
Subsets tool, whereby users submit their FASTA sequences and
a report is generated with IMGT/V-QUEST results and subset
assignment along with an assignment conﬁdence level ranging
from ‘borderline’ to ‘extreme’. Users are urged to use caution
and their best judgement, or ask for advice, especially for
clinical use of, for example, ‘borderline’- or ‘low’-conﬁdence
assignments. The tool together with comprehensive back-
ground and instructions are available at http://tools.bat.infspire.
org/arrest/assignsubsets/.
5. Provide a concise overall assessment of the clinical implications
of the immunogenetic results; several examples and templates
are provided as Supplementary Material. The following issues
merit special consideration:
i. Cases with a single unproductive rearrangement, apparent
double rearrangements or lacking VH CDR3 anchors
(overall frequency: ~ 3% of cases).28 In these instances,
the report should include a relevant statement, depending
on the particular type of ‘issue’, following the published
ERIC recommendations for reliable interpretation of
problematic cases28,30 and/or by consulting the online
ERIC Review Board (www.ericll.org/services/).
ii. Cases with IGHV gene rearrangements with ‘borderline’
identity to the closest germ line counterpart. Classiﬁcation
into the M-CLL or U-CLL category should always be based
on the established 98% cutoff value for identity to the
germ line (M-CLL: o98%; U-CLL: 98–100%). That notwith-
standing, for cases close to the cutoff (for example, 97–
97.99%), caution is warranted regarding the precise
prognostic implications31 and a statement to this effect
should be included in the report (for example, ‘Following
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the 98% cutoff value for discriminating between IG-
mutated or IG-unmutated CLL cases, the SHM status of
this particular rearranged IGHV gene is borderline. The
clinical implications remain to be elucidated’).
CONCLUDING REMARKS
The BcR IG sequence is the ideal clonal marker for CLL: it is present
from the birth of every CLL clone and in contrast to other markers,
most notably genomic aberrations, remains stable over time and
unaffected by disease evolution. Recent evidence has reinforced
the important prognostic/predictive value of immunogenetic
analysis in CLL, while also highlighting the need to move from
the mere determination of IGHV gene mutational status to a more
comprehensive assessment of the IGHV-IGHD-IGHJ gene rearran-
gement including stereotyped subset assignment, at least in for
certain cases.
ERIC has pioneered the adoption of good practices and will
continue to strive to ensure reliable immunogenetic analysis in
CLL for the beneﬁt of patients. That said, this topic is far from
being exhausted, especially due to the advent of novel analytical
approaches, that is, high-throughput sequencing, necessitating
further efforts for standardization, currently an unmet need and
the focus of an ongoing initiative within ERIC.
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